The EMBER trial, a multicenter, open-label phase Ia/b dose-escalation/expansion trial, included patients with ER+ advanced breast cancer (prior endocrine therapy sensitivity; ≤3 prior therapies for advanced breast cancer). The gene discussed is ESR1; the disease is breast carcinoma.